関節リウマチ診断検査市場：検査タイプ別、エンドユーザー別-2025-2030年の世界予測

関節リウマチ診断検査市場は、2023年に29億8,000万米ドルと評価され、2024年には30億8,000万米ドルに達すると予測され、CAGR 4.69％で成長し、2030年には41億1,000万米ドルになると予測されています。

関節リウマチ（RA）診断検査は、関節に影響を及ぼす慢性自己免疫疾患であるRAの存在と進行を検出することを目的とした一連の診断手順を包含します。これらの検査の必要性は、RAが生活の質に与える影響や、治療しなければ関節の損傷や全身合併症を引き起こす可能性があることから生じています。主なアプリケーションには、リウマトイド因子（RF）、抗環状シトルリン化ペプチド（抗CCP）抗体検査などの血液検査、X線やMRIなどの画像検査があります。最終用途は病院、診断研究所、学術研究機関など多岐にわたる。市場成長の主因は、RA有病率の増加、診断技術の向上、患者やヘルスケアプロバイダーの意識の高まりです。高齢化やバイオマーカーの進歩も市場拡大に寄与しています。迅速かつ正確で低侵襲な診断検査の開発や、遠隔モニタリングのための遠隔医療アプリケーションの拡大に新たなビジネスチャンスが存在します。

しかし、高度な診断検査にかかる費用の高さ、偽陽性・偽陰性のリスク、低所得地域における認知度の低さといった課題が、市場の成長を阻害しています。また、償還の問題も検査へのアクセスを制限する可能性があります。こうした課題に対処するため、技術革新はコスト効率の高い診断ソリューション、検査の感度と特異度の向上、デジタルヘルスプラットフォームを通じた患者アクセスの拡大に焦点を当てるべきです。診断会社、ヘルスケアプロバイダー、テクノロジー企業のコラボレーションは、診断精度とアクセシビリティの飛躍的向上を促進することができます。同時に、AIと遺伝子研究を利用したパーソナライズドヘルスケアに注力することで、オーダーメイドのRA管理が期待できます。新規バイオマーカーの調査やマルチオミクスアプローチの統合も、革新のための肥沃な土壌となります。市場は競争的で技術主導型であるため、新技術への投資、パートナーシップの優先、地域医療格差への対応に取り組む企業は、市場での地位を強化できる可能性があります。まとめると、RA診断検査市場は、コストやアクセシビリティに関する課題に直面しながらも、技術的進歩や戦略的イニシアティブを通じて成長する態勢が整っています。

市場力学：急速に進化する関節リウマチ診断検査市場の主要市場インサイトを公開

関節リウマチ診断検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の関節リウマチの有病率の増加
  • RAの治療と管理に対する支出の増加
  • 政府や世界的機関によるRAに関する啓蒙活動
• 市場抑制要因
  • RAに対するヘルスケアサービスへの患者の消極性
• 市場機会
  • MRI、超音波、HR-pQCT画像検査の改善と血清バイオマーカーパネルの開発
  • RA診断のための継続的な研究活動
• 市場の課題
  • 検査キットの特異度と感度の限界

ポーターのファイブフォース：関節リウマチ診断検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：関節リウマチ診断検査市場における外部からの影響の把握

外部マクロ環境要因は、関節リウマチ診断検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析関節リウマチ診断検査市場における競合情勢の把握

関節リウマチ診断検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス関節リウマチ診断検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、関節リウマチ診断検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨関節リウマチ診断検査市場における成功への道筋を描く

関節リウマチ診断検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で関節リウマチの罹患率が増加
    • RAの治療と管理にかかる支出の増加
    • 政府や国際機関によるRAに関する啓発活動
  • 抑制要因
    • RAのヘルスケアサービスを受けることに消極的な患者
  • 機会
    • MRI、超音波、HR-pQCT画像検査の改善と血清バイオマーカーパネルの開発
    • RAの診断のための継続的な調査活動
  • 課題
    • 検査キットの特異性と感度の限界
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 関節リウマチ診断検査市場テストタイプ別

• 関節リウマチ治療効率のモニタリング検査
  • クレアチニン検査
  • 筋酵素検査
  • サリチル酸レベルカウント
• 血清検査
  • 抗環状シトルリン化ペプチド
  • 抗核抗体
  • 赤血球沈降速度
  • リウマチ因子（RF）
  • 尿酸

第7章 関節リウマチ診断検査市場：エンドユーザー別

• 診断センター
• 病院・クリニック

第8章 南北アメリカの関節リウマチ診断検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の関節リウマチ診断検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの関節リウマチ診断検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Apollo Health and Lifestyle Limited
• Arthritis Society Canada
• Augurex Life Sciences Corporation
• Beckman Coulter, Inc.
• Bio-Rad Laboratories Inc.
• Exagen Inc.
• F. Hoffmann-La Roche AG
• Genway Biotech, Inc.
• Laboratory Corporation of America Holdings
• QIAGEN GmbH
• Remission Medical
• Siemens Healthineers
• Svar Life Sciences AB
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET RESEARCH PROCESS
• FIGURE 2. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET DYNAMICS
• TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CREATININE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MUSCLE ENZYME TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SALICYLATE LEVEL COUNT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTI-CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR (RF), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY URIC ACID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 39. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 60. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 61. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 64. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 65. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 133. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 134. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 149. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 150. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 153. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 154. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

The Rheumatoid Arthritis Diagnosis Tests Market was valued at USD 2.98 billion in 2023, expected to reach USD 3.08 billion in 2024, and is projected to grow at a CAGR of 4.69%, to USD 4.11 billion by 2030.

Rheumatoid Arthritis (RA) diagnosis tests encompass a range of diagnostic procedures aimed at detecting RA's presence and progression, a chronic autoimmune disorder affecting joints. The necessity for these tests arises from RA's impact on quality of life and potential to cause joint damage and systemic complications if untreated. Key applications include blood tests such as rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody testing, and imaging tests like X-rays and MRIs. End-use spans across hospitals, diagnostic laboratories, and academic research institutes. Market growth is primarily driven by increasing RA prevalence, improvements in diagnostic technologies, and heightened awareness among patients and healthcare providers. The aging population and advancements in biomarkers contribute to market expansion. Emerging opportunities exist in developing rapid, accurate, minimally invasive diagnostic tests, and expanding telemedicine applications for remote monitoring.

However, market growth is impeded by challenges such as high costs of advanced diagnostic tests, risk of false positives or negatives, and limited awareness in low-income regions. Reimbursement issues can also limit test accessibility. To address these challenges, innovation should focus on cost-effective diagnostic solutions, enhancing the sensitivity and specificity of the tests, and increasing patient access through digital health platforms. Collaboration between diagnostic companies, healthcare providers, and technology firms can foster breakthroughs in diagnostic accuracy and accessibility. Concurrently, a focus on personalized healthcare using AI and genetic research holds promise for tailored RA management. Research into novel biomarkers and integration of multi-omic approaches also represents fertile ground for innovation. As the market is competitive and technology-driven, businesses that invest in emerging technologies, prioritize partnerships, and address regional healthcare disparities could strengthen their market position. In summary, the RA diagnosis test market is poised for growth through technological advancements and strategic initiatives despite facing challenges related to cost and accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rheumatoid Arthritis Diagnosis Tests Market

The Rheumatoid Arthritis Diagnosis Tests Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of rheumatoid arthritis worldwide
  • Growing expenditure for the treatment and management of RA
  • Awareness initiatives about RA by governments and global institutions
• Market Restraints
  • Patients' reluctance to access healthcare services for RA
• Market Opportunities
  • Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
  • Ongoing research activities for the diagnosis of RA
• Market Challenges
  • Limited specificity and sensitivity of test kits

Porter's Five Forces: A Strategic Tool for Navigating the Rheumatoid Arthritis Diagnosis Tests Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rheumatoid Arthritis Diagnosis Tests Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rheumatoid Arthritis Diagnosis Tests Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rheumatoid Arthritis Diagnosis Tests Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rheumatoid Arthritis Diagnosis Tests Market

A detailed market share analysis in the Rheumatoid Arthritis Diagnosis Tests Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rheumatoid Arthritis Diagnosis Tests Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rheumatoid Arthritis Diagnosis Tests Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rheumatoid Arthritis Diagnosis Tests Market

A strategic analysis of the Rheumatoid Arthritis Diagnosis Tests Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rheumatoid Arthritis Diagnosis Tests Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apollo Health and Lifestyle Limited, Arthritis Society Canada, Augurex Life Sciences Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Exagen Inc., F. Hoffmann-La Roche AG, Genway Biotech, Inc., Laboratory Corporation of America Holdings, QIAGEN GmbH, Remission Medical, Siemens Healthineers, Svar Life Sciences AB, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Rheumatoid Arthritis Diagnosis Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Monitoring Rheumatoid Arthritis Treatment Efficiency Tests and Serology Test. The Monitoring Rheumatoid Arthritis Treatment Efficiency Tests is further studied across Creatinine Test, Muscle Enzyme Tests, and Salicylate Level Count. The Serology Test is further studied across Anti-Cyclic Citrullinated Peptide, Antinuclear Antibody, Erythrocyte Sedimentation Rate, Rheumatoid Factor (RF), and Uric Acid.
• Based on End-User, market is studied across Diagnostic Centers and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of rheumatoid arthritis worldwide
    • 5.1.1.2. Growing expenditure for the treatment and management of RA
    • 5.1.1.3. Awareness initiatives about RA by governments and global institutions
  • 5.1.2. Restraints
    • 5.1.2.1. Patients' reluctance to access healthcare services for RA
  • 5.1.3. Opportunities
    • 5.1.3.1. Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
    • 5.1.3.2. Ongoing research activities for the diagnosis of RA
  • 5.1.4. Challenges
    • 5.1.4.1. Limited specificity and sensitivity of test kits
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Rheumatoid Arthritis Diagnosis Tests Market, by Test Type

• 6.1. Introduction
• 6.2. Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
  • 6.2.1. Creatinine Test
  • 6.2.2. Muscle Enzyme Tests
  • 6.2.3. Salicylate Level Count
• 6.3. Serology Test
  • 6.3.1. Anti-Cyclic Citrullinated Peptide
  • 6.3.2. Antinuclear Antibody
  • 6.3.3. Erythrocyte Sedimentation Rate
  • 6.3.4. Rheumatoid Factor (RF)
  • 6.3.5. Uric Acid

7. Rheumatoid Arthritis Diagnosis Tests Market, by End-User

• 7.1. Introduction
• 7.2. Diagnostic Centers
• 7.3. Hospitals & Clinics

8. Americas Rheumatoid Arthritis Diagnosis Tests Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Rheumatoid Arthritis Diagnosis Tests Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Apollo Health and Lifestyle Limited
• 3. Arthritis Society Canada
• 4. Augurex Life Sciences Corporation
• 5. Beckman Coulter, Inc.
• 6. Bio-Rad Laboratories Inc.
• 7. Exagen Inc.
• 8. F. Hoffmann-La Roche AG
• 9. Genway Biotech, Inc.
• 10. Laboratory Corporation of America Holdings
• 11. QIAGEN GmbH
• 12. Remission Medical
• 13. Siemens Healthineers
• 14. Svar Life Sciences AB
• 15. Thermo Fisher Scientific, Inc.